Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries

Abstract

The private for-profit sector is an important source of treatment for malaria. However, private patients face high prices for the recommended treatment for uncomplicated malaria, artemisinin combination therapies (ACTs), which makes them more likely to receive cheaper, less effective non-artemisinin therapies (nATs). This study seeks to better understand consumer antimalarial prices by documenting and exploring the pricing behaviour of retailers and wholesalers. Using data collected in 2009–10, we present survey estimates of antimalarial retail prices, and wholesale- and retail-level price mark-ups from six countries (Benin, Cambodia, the Democratic Republic of Congo, Nigeria, Uganda and Zambia), along with qualitative findings on factors affecting pricing decisions. Retail prices were lowest for nATs, followed by ACTs and artemisinin monotherapies (AMTs). Retailers applied the highest percentage mark-ups on nATs (range: 40% in Nigeria to 100% in Cambodia and Zambia), whereas mark-ups on ACTs (range: 22% in Nigeria to 71% in Zambia) and AMTs (range: 22% in Nigeria to 50% in Uganda) were similar in magnitude, but lower than those applied to nATs. Wholesale mark-ups were generally lower than those at retail level, and were similar across antimalarial categories in most countries. When setting prices wholesalers and retailers commonly considered supplier prices, prevailing market prices, product availability, product characteristics and the costs related to transporting goods, staff salaries and maintaining a property. Price discounts were regularly used to encourage sales and were sometimes used by wholesalers to reward long-term customers. Pricing constraints existed only in Benin where wholesaler and retailer mark-ups are regulated; however, unlicensed drug vendors based in open-air markets did not adhere to the pricing regime. These findings indicate that mark-ups on antimalarials are reasonable. Therefore, improving ACT affordability would be most readily achieved by interventions that reduce commodity prices for retailers, such as ACT subsidies, pooled purchasing mechanisms and cost-effective strategies to increase the distribution coverage area of wholesalers.

Untitled

“…Another study reported that antimalarials such as quinine, artemether, and sulfadoxinepyrimethamine were available in the three health care facilities examined although in varying amounts 2 . Their finding is similar to that of 15 which showed that quinine and sulfadoxinepyrimethamine were more frequently available in retail outlets compared to the new generation antimalarials (ACTs).…”

Availability, prices and affordability of UN Commission’s lifesaving medicines for reproductive and maternal health in Uganda

“…This finding is consistent with many studies done in low and middle income countries which show that medicine prices are often high [ 27 – 29 ]. Efforts should be undertaken by the Ministry of Health and stakeholders like manufacturers, development partners and civil society to reduce commodity prices through measures such as price caps, subsidies, pooled purchasing mechanisms by all sectors and cost-effective strategies to increase the distribution coverage area of wholesalers [ 30 , 31 ].…”

New forms of development: branding innovative ideas and bidding for foreign aid in the maternal and child health service in Nepal

“…For a sustained and quality health service, we argue that foreign aid should focus on supporting and strengthening national government systems in Nepal and other low-income countries. There is plenty of evidence that around 99% of maternal deaths occur in low-income countries with weaker national health systems [24]. Improving the overall standard is key.…”